semaglutide heart failure fda approves Wegovy to reduce attack and stroke risk FDA Approves Semaglutide for Cardiovascular

How to Use This product is administered via subcutaneous injection using the pre-filled pen system

When it comes to injectable medications, there is a critical safety rule that often is not explained clearly enough: once a multi-dose vial is punctured, it should be discarded after 28 days, even if the vial is not completely empty

Side Effects Comparison# Retatrutide Side Effects# Phase 2 trial data revealed: Gastrointestinal : Nausea (24-46%), diarrhea (16-26%), vomiting (9-20%), constipation (6-16%) Heart rate : Small mean increase (2-4 bpm) potentially related to glucagon receptor activation Injection site reactions : Mild and transient Hepatic : Transient elevations in liver enzymes observed Discontinuation rate : 6-10% due to adverse events in Phase 2 The glucagon receptor component introduces a unique side effect profile compared to GLP-1-only or GIP/GLP-1 dual agonists

doi: 10.1038/sj.cdd.4401153

By increasing the levels of GLP-1 in your body, Semaglutide helps reduce hunger and increase feelings of fullness, leading to significant weight loss

Good Luck to everyone dealing with this